Back to search results

Immunai

STEX25
Active dates:

November 4, 2020 - November 4, 2020
STEX25
View Feature
STEX25 Participation:
November 4, 2020 - November 3, 2021
Company information
Contact

180 Varick Street, 6th Floor
New York, NY 10014
United States

https://www.immunai.com/
Keywords
single-cell sequencing, single-cell genomics, machine learning, Artificial Intelligence
Elevator Pitch

Elevator Pitch

Immunai is a distributed biotechnology company that develops immune-mediated precision therapeutics. Immunai believes that its deep understanding of the immune system, powered by its functional genomics and AI engine, will drive an explosion in both successful target discoveries and novel therapeutic development. Headquartered in New York City, with offices in San Francisco and Tel Aviv, the company has raised $90M in funding to-date.
Description

Description

Immunai is an end-to-end computational immunology company leveraging the power of single-cell biology and AI to decode the Immune System to improve health and accelerate therapeutics.
Technology Description

Technology Description

We couple single-cell sequencing methods and technology-development that is proprietary with machine learning and AI to generate gene and surface-protein expression data for thousands of immune cells and create an immune profile. We then apply deep learning models to correlate immune surrogate endpoints with clinical endpoints to accelerate clinical trials and find novel targets